[ad_1]
Samsung Bioepis introduced on Jan. 26 that it achieved record-high efficiency when it comes to gross sales final yr, pushed by expanded biosimilar gross sales within the world market.
In accordance with Samsung Epis Holdings’ earnings announcement, Samsung Bioepis recorded consolidated gross sales of 1.672 trillion gained and working revenue of 375.9 billion gained final yr. Gross sales elevated 9% in comparison with the earlier yr, setting a brand new annual document. Working revenue decreased 14% as a result of influence of diminished one-time milestone income.
Nevertheless, product gross sales efficiency excluding milestones, gross sales elevated 28% in comparison with the earlier yr, and working revenue elevated 101%.
Samsung Bioepis is increasing biosimilar gross sales in main world markets together with the US and Europe. In the US, the world’s largest pharmaceutical market, the corporate is increasing market share by means of a “two-track” technique that concurrently targets provide channels for personal insurance coverage corporations’ pharmacy profit administration (PBM) corporations together with collaboration with native advertising companions.
Final yr, the corporate newly launched Stelara and Soliris biosimilars within the U.S. market by means of partnerships with world pharmaceutical corporations. The Stelara biosimilar succeeded in early market institution by securing secure distribution channels by means of concluding personal label (PL) contracts with main PBMs.
Efficiency continues within the European market, which accounts for greater than 60% of complete gross sales. Samsung Bioepis is pursuing thorough provide chain administration, partnerships, and direct gross sales methods in parallel.
The corporate elevated the variety of merchandise bought in Europe to 10 since launching its first product (SB4, Enbrel biosimilar) in 2016, over a 10-year interval. Amongst these, 4 merchandise together with Soliris, Prolia, Xgeva, and Lucentis biosimilars are being bought straight by means of native gross sales networks.
In the meantime, Samsung Epis Holdings, the bio holding firm launched in November final yr, disclosed its first earnings outcomes this time. In the course of the two months since launch, it recorded consolidated gross sales of 251.7 billion gained and working lack of 63.6 billion gained.
The corporate defined, “That is non permanent loss resulting from accounting changes arising from the company spin-off course of and elevated analysis and growth bills,” including “It’s unrelated to precise money circulate.”
Samsung Epis Holdings plans to actively help its subsidiaries’ core companies this yr and start strengthening enterprise competitiveness in earnest below the holding firm construction. The corporate plans to proceed its development trajectory with the aim of increasing biosimilar gross sales within the world market by greater than 10% in comparison with the earlier yr.
[ad_2]
